VIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vir Biotechnology Inc (VIR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent positive analyst ratings, strong technical indicators, and promising oncology developments outweigh the negative sentiment from insider and hedge fund selling. The stock's current pre-market price of $10.35 presents a solid entry point given its potential upside.
The MACD is positive and contracting, indicating bullish momentum. The RSI is neutral at 51.973, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 10.351, with resistance at 11.345 and support at 9.358. Overall, the technical indicators suggest a favorable trend for entry.
Multiple analysts have raised price targets significantly, with targets ranging from $17 to $30, citing strong Phase 1 data for VIR-5500 and a promising oncology pipeline.
The Astellas collaboration provides significant upfront payments and profit-sharing opportunities, enhancing the company's financial and strategic position.
The company's gross margin has improved to 99.96%, indicating strong operational efficiency.
Hedge funds and insiders are selling the stock, with hedge fund selling increasing by 3690.48% and insider selling rising by 209.11%.
The company reported a net income loss of -$42.92M in Q4 2025, with EPS dropping by -59.21% YoY.
In Q4 2025, revenue increased by 417.78% YoY to $64.07M, showcasing strong top-line growth. However, net income dropped by -58.96% YoY to -$42.92M, and EPS fell by -59.21% YoY to -0.31. Despite these losses, the gross margin improved to 99.96%, up 5.81% YoY, reflecting operational efficiency.
Analysts are overwhelmingly positive on VIR, with multiple firms raising price targets and maintaining Buy or Strong Buy ratings. The average price target is significantly above the current price, with analysts highlighting the company's oncology pipeline, strong Phase 1 data, and strategic collaborations as key drivers of future growth.
